October 20, 2021
Nippon Boehringer Ingelheim said on October 19 that the first patient in Japan has been enrolled in its global PIII CONNEX program investigating its glycine transporter-1 (GlyT1) inhibitor BI 425809 for the treatment of cognitive impairment associated with schizophrenia (CIAS)...read more